Key result
Endonuclease-based gene-editing platforms offer distinct strengths and weaknesses for therapeutic applications in genetic medicine.
This review provides an accessible overview of endonuclease-based gene-editing platforms and their parameters impacting clinical implementation.
May enable curative gene correction in monogenic CV disorders; leaves open the need for rigorous clinical validation.
Emerging gene-editing technologies are nearing a revolutionary phase in genetic medicine: precisely modifying or repairing causal genetic defects. This may include any number of DNA sequence manipulations, such as knocking out a deleterious gene, introducing a particular mutation, or directly repairing a defective sequence by site-specific recombination. All of these edits can currently be achieved via programmable rare-cutting endonucleases to create targeted DNA breaks that can engage and exploit endogenous DNA repair pathways to impart site-specific genetic changes. Over the past decade, several distinct technologies for introducing site-specific DNA breaks have been developed, yet the different biological origins of these gene-editing technologies bring along inherent differences in parameters that impact clinical implementation. This review aims to provide an accessible overview of the various endonuclease-based gene-editing platforms, highlighting the strengths and weakness of each with respect to therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Certo et al. (2016) conducted a review in Genetic defects. Endonuclease-based gene-editing platforms was evaluated. Endonuclease-based gene-editing platforms offer distinct strengths and weaknesses for therapeutic applications in genetic medicine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: